Drugs / METELIMUMAB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00043706 | ? → Sep 2003 | systemic sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METELIMUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108431 ↗ |
| Known as | CAT-192 | “Genzyme Corporation is currently investigating a human monoclonal antibody (CAT-192) that neutralizes active TGF-beta1.” NCT00043706 ↗ |
| Action | Inhibit | “Transforming growth factor beta-1 inhibitor” CHEMBL2108431 ↗1“neutralizes active TGF-beta1” NCT00043706 ↗ |
| Modality | Monoclonal antibody | “a human monoclonal antibody (CAT-192)” NCT00043706 ↗ |
| Target | TGFB1 | “Transforming growth factor beta-1 inhibitor” CHEMBL2108431 ↗ |